Skip to main content

Table 3 Univariate analyses of overall survival in patients with resected GBC and liver metastasis

From: Examination of the characteristics of long-term survivors among patients with gallbladder cancer with liver metastasis who underwent surgical treatment: a retrospective multicenter study (ACRoS1406)

  

n

3 years OS

p valuea

Period

2000–2006′/2007–2013′

15/11

7.86/45.5

0.04

Age (year)

< 70/≥ 70

15/1

26.7/22.2

0.90

Sex

Male/female

13/13

30.8/18.2

0.90

Preop. jaundice

No/Yes

17/9

40.2/0

0.05

NAC

No/Yes

23/3

28.8/0

0.70

CA19-9, U/L

≤ 37/> 37

8/18

28.6/23.6

1.0

CEA, ng/mL

> 5/≤ 5

15/11

26.7/22.2

0.80

hepatectomy

minor/major

13/13

50.0/0

< 0.001

BDR

With/without/PD

15/8/3

14.3/43.8/33.3

0.2

Blood loss, mL

< 864/≥ 864

9/17

71.4/5.88

< 0.001

Surgery time, min

< 366/≥ 366/

13/13

45.8/7.69

0.007

Histology

Pap/other than pap

5/21

60.0/15.4

0.05

AJCC T 8th

T2/ T3,4

8/18

71.4/5.88

0.002

AJCC N 8th

N0/N1/N2

9/12/3

22.2/30.7/0/33.3

0.90

P

without /with

23/3

28.6/0

0.03

Residual cancer

R0/R1

16/10

28.7/20.0

0.30

Morbidity*

≤ 2/≥ 3

21/5

31.8/0

0.09

AC

with/without

15/10

40.0/0

0.09

  1. Bold values indicate p < 0.05
  2. OS, overall survival; NAC, Neoadjuvant chemotherapy; CA, cancer antigen; CEA, carcinoembryonic antigen; AJCC, American Joint Committee on Cancer
  3. *Clavien–Dindo classification; AC, Adjuvant chemotherapy. pap/tub1/tub2/tub3, T2/T3/T4, N0/N1/N2, R0/R1,2 (Additional file 1: Table S1)
  4. aLog-rank test